Helicobacter pylori eradication therapy with vonoprazan, clarithromycin, and metronidazole for chronic kidney disease patients

Efficacy and safety of Helicobacter pylori eradication therapy with vonoprazan, clarithromycin, and metronidazole for patients with chronic kidney disease without dialysis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200239

Enrollment

Registered

2020-12-11

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection Helicobacter pylori

Interventions

Vonoprazan (20mg), clarithromycin (200mg), and metronidazole (250mg) given on twice daily for 7days

Helicobacter pylori eradication therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, anti-Helicobacter pylori antibody test (blood), Helicobacter pylori culture, rapid urease test, or histrogical diagnosis of Helicobacter pylori are treated with infected. Patients who underwent upper gastrointestinal endoscopy and diagnosed as gastritis, gastric ulcer, duodenal ulcer, gastric MALT lymphoma, after endoscopic treatment for early gastric cancer, or idiopathic thrombocytopenic purpura. Patients whose eGFR revel is from 10mL/min/1.73m2 to 45mL/min/1.73m2 at the study entry, and diagnosed as chronic kidney disease. Patients who give a written informed consent.

Exclusion criteria

Exclusion criteria: Patients who have Helicobacter pylori eradication history. Hemodialysis patients for renal failure. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Patients using atazanavir, rilpivirine, pimozide, ergotamine, suvorexant, lomitapide mesylate, tadalafil, ticagrelor, ibrutinib, asuna previr, ivavradine, venetoclax, colchicine, lurasidone hydrochloride, anamorelin hydrochloride, finerenone, or isavuconazonium sulfate. A patient with brain and spinal cord disease. Patients who are disqualified for the study by physicians.

Design outcomes

Primary

Measure	Time frame
Eradication rate (FAS)	—

Secondary

Measure	Time frame
(1) Eradication rate (PPS) (2) Safety	—

Contacts

Public ContactSoichiro Sue

Yokohama City University Hospital

ssue@yokohama-cu.ac.jp+81-457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026